Due to the heterogeneity of NAFLD pathophysiology, the benefits of the GLP-1 receptor agonist on metabolic markers have an important impact in liver outcomes, such as liver function test, steatosis, and NASH improvement; nonetheless, more evidence is necessary to assess the effects of these drugs in fibrosis resolution (80, 81). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.